Cabergoline May Reduce Breast Cancer Risk After Childbirth
A study shows a 70 percent lower cancer risk for women who used the drug to suppress milk production.
Updated on Oct. 15, 2026 in Cancer
Live Poll
Would you consider using a repurposed drug for breast cancer prevention if confirmed by clinical trials?
A large-scale study finds that women who used the medication cabergoline to suppress milk production after pregnancy had a 70 percent lower risk of developing breast cancer. Researchers are now planning clinical trials to determine if the drug could serve as a preventative strategy for those at higher risk.
Why it matters
Incomplete breast tissue involution after breastfeeding can leave behind cells that potentially become cancerous, a risk factor this drug may mitigate. This finding could provide a new pathway for breast cancer prevention in women, particularly those with genetic predispositions.
This retrospective study analyzed health records from 150,000 women in Spain and Norway to identify a 70 percent lower breast cancer risk associated with cabergoline use. Separately, preclinical mouse models showed a 50 percent reduction in tumor incidence, though human clinical trial results are not yet available.
The players
The Gray Foundation
A philanthropic organization funding the upcoming multinational clinical trial for the use of cabergoline as a cancer prevention strategy.
The details
Cabergoline works by accelerating the natural process of breast involution that occurs after weaning, which reduces the ductal area and limits cell growth. By shrinking this tissue, the drug reduces the presence of residual cells that may otherwise become cancerous. Preclinical tests also suggest the drug boosts immune cells that are responsible for clearing damaged, potentially precancerous tissue.
Timeline
October 15, 2026: The study results were published in the journal Cancer Discovery.
Health Landscape
The study marks a significant step toward using existing, well-understood medications to target specific biological vulnerabilities in cancer development. It shifts the focus of breast cancer prevention toward managing the postpartum period, following a pattern established by the Gray Foundation's multinational clinical trial.
While this research offers a promising new direction, it is not currently a clinical recommendation for breast cancer prevention. Anyone interested in understanding their breast cancer risk factors or postpartum health should consult with their physician.
The takeaway
This study identifies a potential biological link between postpartum milk suppression and lower breast cancer risk. Readers should continue to follow routine breast cancer screening guidelines and discuss any concerns about individual risk factors with their healthcare provider.
Further reading
For more information on current breast health research and prevention, visit our Cancer section.
More information
Review the full study published in Cancer Discovery for comprehensive details on the methodology.
Live Poll
Would you consider using a repurposed drug for breast cancer prevention if confirmed by clinical trials?
